ARGX vs BCRX
argenx SE vs BioCryst Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
BCRX
BioCryst Pharmaceuticals, Inc.
55
Watch
| Metric | ARGX | BCRX |
|---|
| AI Score |
69
|
55
|
| Price |
$864.40
|
$10.35
|
| P/E Ratio |
31.34×
|
-7.19×
|
| ROE |
17.6%
|
-221.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
23.5%
|
| Debt / Equity |
0.01×
|
-0.90×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
75.0
|
| Beta |
-0.022
|
0.554
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus BCRX.
ARGX leads by 14 points.
ARGX scores 69/100 (Buy) versus BCRX at 55/100 (Watch).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
BCRX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 68.7% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.09) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 68.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 13.9x prices in significant intangible value — Value
- ROE of only -328.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.09 adds balance-sheet risk to the value case — Value